News
Following the successful completion of the Phase 3 BROADWAY, TANDEM, and BROOKLYN trials NewAmsterdam plans to announce additional data over the course of 2025 relating to obicetrapib and the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback